SN-38 loaded polymeric micelles to enhance cancer therapy

  1. Get@NRC: SN-38 loaded polymeric micelles to enhance cancer therapy (Opens in a new window)
DOIResolve DOI:
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for:
Journal titleNanotechnology
Article number205101
SubjectAqueous suspensions; Cancer cells; Cancer therapy; Caprolactone; Drug loading; Drug release; Encapsulation efficiency; Fetal bovine serum; Hydration method; In-vitro; Inhibitory concentration; Low toxicity; Lung cells; Modified film; Phosphate-buffered salines; Pluronics; Polymeric micelle; Propylene glycols; Transmission electron microscopy (TEM); Atomic force microscopy; Dynamic light scattering; Encapsulation; Loading; Nanoparticles; Transmission electron microscopy; Polyethylene glycols; antineoplastic agent; camptothecin; drug derivative; irinotecan; nanocapsule; apoptosis; article; cell survival; chemistry; diffusion; drug effect; experimental neoplasm; human; metabolism; micelle; tumor cell culture; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Diffusion; Humans; Micelles; Nanocapsules; Neoplasms, Experimental; Tumor Cells, Cultured
Abstract7-Ethyl-10-hydroxycamptothecin (SN-38) loaded poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) (Pluronic F-108) and poly(ethylene glycol)-block-poly("-caprolactone) (PEG-b-PCL) nanoparticles were successfully prepared by a modified film hydration method and characterized by scanning electric microscopy (SEM), transmission electron microscopy (TEM), atomic force microscopy (AFM) and dynamic light scattering (DLS). Satisfactory drug loading of 20.73 ± 0.66% and a high encapsulation efficiency of 83:83 ± 1:32% were achieved. The SN-38 nanoparticles (SN-38 NPs) can completely disperse into a phosphate buffered saline (PBS) medium to produce a clear aqueous suspension that remains stable for up to three days. Total drug releases were 67.91% and 91.09% after 24 h in a PBS or fetal bovine serum (FBS) medium. Half maximal inhibitory concentration (IC50) tests of SN-38 and SN-38 NPs on A549 lung cells produced results of 200.0±14.9 ng ml -1 and 80.0±4.6 ng ml -1, respectively. Similarly, IC50 tests of SN-38 and SN-38 NPs on MCF-7 breast cells yielded results of 16.0 ± 0.7 ng ml -1 and 8.0 ± 0.5 ng ml -1, respectively. These in vitro IC 50 studies show significant (p < 0.01) enhancement of the SN-38 NP drug efficiency in killing cancer cells in comparison to the free drug SN-38 control. All the materials used for this nanoformulation are approved by the US FDA, with the virtue of extremely low toxicity to normal cells. © 2012 IOP Publishing Ltd.
Publication date
AffiliationNational Research Council Canada (NRC-CNRC); National Institute for Nanotechnology (NINT-INNT)
Peer reviewedYes
NPARC number21269485
Export citationExport as RIS
Report a correctionReport a correction
Record identifier7a32c2f4-ed33-4747-b065-75df8c14a016
Record created2013-12-12
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)